SCHEMBL4197358

SCHEMBL4197358

CCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2ccccc2CNC(C)CC2CCCCC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
CYP3A4 P08684 1/20 0.46
ALOX15 P16050 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
AKT1 P31749 4/20 0.45
LMNA P02545 1/20 0.45
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
HTT P42858 2/20 0.43
FNTA P49354 1/20 0.42
FNTB P49356 1/20 0.42
RCE1 Q9Y256 1/20 0.42
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190140 0.89 LMNA (0.45) MEN1USP2CYP3A4ALOX15KMT2A
SCHEMBL14344188 0.87 LMNA (0.43) MEN1USP2CYP3A4ALOX15KMT2A
SCHEMBL14343791 0.87 PKM (0.52) MEN1KMT2ALMNAKDM4EPKM
SCHEMBL4197354 0.87 KDM4E (0.49) MEN1KMT2ALMNAKDM4EPKM
SCHEMBL14344034 0.86 KDM4E (0.48) MEN1KMT2ALMNAKDM4EPKM
SCHEMBL4193563 0.84 KDM4E (0.47) MEN1CYP3A4KMT2ALMNAKDM4E
SCHEMBL4708520 0.84 AKT1 (0.47) MEN1USP2CYP3A4ALOX15KMT2A
SCHEMBL12050337 0.84 KDM4E (0.48) LMNAKDM4EPKMALDH1A1
SCHEMBL4188159 0.84 KDM4E (0.48) LMNAKDM4EPKMALDH1A1
SCHEMBL4188316 0.83 KDM4E (0.51) MEN1KMT2ATDP1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 MEN1 3776/4885USP2 3049/4885CYP3A4 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.